<DOC>
	<DOCNO>NCT01478191</DOCNO>
	<brief_summary>This retrospective analysis homogeneous cohort patient relapsed/refractory HL receive IGEV scheme induction therapy HDCT AHSCT reassess common prognostic factor try identify prognostic score clinical therapeutic relevance use 6 clinical tool : 1 . B symptom ( yes/no ) 2. relapse previously irradiate area ( yes/no ) 3 . Ann Arbor Stage ( III/IV v I/II ) 4. disease status accrual ( refractory v relapse ) 5 . Early relapse within 12 month Complete Response ( CR ) versus late relapse Complete Response ( CR ) last &gt; l2 month '' , 6. extranodal involvement ( yes/no ) .</brief_summary>
	<brief_title>Prognosis Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patient history classical HL relapsed/refractory receive IGEV regimen induction therapy high dose chemotherapy AHSCT Age &gt; 18 year Patients relapsed/refractory disease standard treatment ( chemotherapy +/ radiotherapy ) IGEV induction regimen . ( Relapsed = disease relapse CR . Refractory = non CR last chemotherapy line , progression last treatment , disease progression within three month previous treatment completion ) . Availability clinical data , laboratory value CT scan result patient enrol , perform diagnosis last followup Patient schedule receive three four IGEV cycle pretransplantation induction regimen . First IGEV course start December 31st 2007 Assessment tumor response Cheson 1999 criterion 11</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Ifosfamide , Gemcitabine Vinorelbine ( IGEV )</keyword>
	<keyword>High Dose Chemotherapy ( HDCT )</keyword>
	<keyword>Autologous Hematopoietic Stem Cells Transplantation ( AHSCT )</keyword>
</DOC>